Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

BACKGROUND: In advanced breast cancer, multiple sequential lines of treatments are frequently applied. Pegylated liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher lines of therapy. PLD has demonstrated response activity even after prior anthracycline ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiegl, Michael, Mlineritsch, Brigitte, Hubalek, Michael, Bartsch, Rupert, Pluschnig, Ursula, Steger, Günther G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178544/
https://www.ncbi.nlm.nih.gov/pubmed/21864402
http://dx.doi.org/10.1186/1471-2407-11-373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178544/
https://www.ncbi.nlm.nih.gov/pubmed/21864402
http://dx.doi.org/10.1186/1471-2407-11-373

Ejemplares similares